21 . 03 .2024
Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow
19 . 03 .2024
Press release
AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio
13 . 03 .2024
Press release
Galderma launches IPO on the SIX Swiss Exchange and sets price range
10 . 03 .2024
Press release
Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis
29 . 02 .2024
Press release
Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion
28 . 02 .2024
Press release
Galderma to showcase latest updates from its broad, innovative and leading dermatology portfolio at the 2024 American Academy of Dermatology annual meeting
14 . 02 .2024
Press release
Galderma announces regulatory filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU
08 . 02 .2024
Press release
Galderma takes the ‘Face of Cetaphil®’ to the runway at New York City fashion week
07 . 02 .2024
Press release
Galderma launches ‘NEXT’, a ground-breaking trend report that unveils the future of aesthetics